Literature DB >> 9531078

Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy.

G Bacci1, A Briccoli, M Mercuri, S Ferrari, F Bertoni, A Gasbarrini, N Fabbri, M Cesari, C Forni, M Campanacci.   

Abstract

Between September 1986 and September 1991, 44 patients with lung metastases originating from an osteosarcoma of an extremity were treated with: primary chemotherapy, simultaneous resection of primary and metastatic lesions (when feasible), and then further chemotherapy. After primary chemotherapy, lung metastases disappeared in 5 patients, whereas in 11 patients they remained surgically unresectable. All 16 patients received local treatment of the primary tumor only. In the remaining 28 patients simultaneous surgical treatment of the primary and the metastatic tumor was performed. The removal of metastatic lesions was complete in 25 and incomplete in 3 patients. With a median follow-up of 8 years (5.5-10.8) all 14 patients who never achieved a tumor-free status died. Of the 30 patients who achieved remission 5 (17%) remained continuously free of disease and 25 developed new metastases, associated with local recurrence in 4 cases. The 5-year overall survival for all 44 patients of the study was 14%, and the 5-year disease-free survival for the 30 patients who reached remission was 17%. These results are significantly worse than those achieved with the same chemotherapy protocol in 144 contemporary patients with localized disease at presentation (73% disease-free and 79% overall survival). We conclude that, despite aggressive chemotherapy which is successful in patients with localized disease, the prognosis remains very poor for patients with osteosarcoma of the extremities with lung metastases at presentation, and justifies the use of novel therapies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531078     DOI: 10.1179/joc.1998.10.1.69

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  9 in total

1.  Estimation of potential excess cancer incidence in pediatric 201Tl imaging.

Authors:  Sue C Kaste; George L Waszilycsak; M Beth McCarville; Najat C Daw
Journal:  AJR Am J Roentgenol       Date:  2010-01       Impact factor: 3.959

2.  Telangiectatic osteosarcoma: a review of 87 cases.

Authors:  Andrea Angelini; Andreas F Mavrogenis; Giulia Trovarelli; Stefano Ferrari; Piero Picci; Pietro Ruggieri
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-28       Impact factor: 4.553

3.  The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells.

Authors:  Xiaodong Mu; Daniel Brynien; Kurt R Weiss
Journal:  Biomed Res Int       Date:  2015-02-17       Impact factor: 3.411

4.  Metastatic Sternal Osteosarcoma: A Rare Tumor.

Authors:  Muhammad Masab; Ena Arora; Sorab Gupta; Hafsa Farooq; Vishal Jindal; Shorabh Sharma
Journal:  Cureus       Date:  2018-02-19

5.  ALDH1A1 Gene Expression and Cellular Copper Levels between Low and Highly Metastatic Osteosarcoma Provide a Case for Novel Repurposing with Disulfiram and Copper.

Authors:  Jonathan B Mandell; Nerone Douglas; Vrutika Ukani; Jan H Beumer; Jianxia Guo; John Payne; Rebecca Newman; Luigi Mancinelli; Giuseppe Intini; Carolyn J Anderson; Rebecca Watters; Kurt Weiss
Journal:  Sarcoma       Date:  2022-01-28

6.  Osteosarcoma of jaws.

Authors:  Mayur Chaudhary; Shweta Dixit Chaudhary
Journal:  J Oral Maxillofac Pathol       Date:  2012-05

7.  A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma.

Authors:  Anne McTiernan; Jeremy S Whelan
Journal:  Sarcoma       Date:  2004

8.  Disintegrin targeting of an αvβ3 integrin-over-expressing high-metastatic human osteosarcoma with echistatin inhibits cell proliferation, migration, invasion and adhesion in vitro.

Authors:  Yasunori Tome; Hiroaki Kimura; Tasuku Kiyuna; Naotoshi Sugimoto; Hiroyuki Tsuchiya; Fuminori Kanaya; Michael Bouvet; Robert M Hoffman
Journal:  Oncotarget       Date:  2016-07-19

9.  Combination Therapy with Disulfiram, Copper, and Doxorubicin for Osteosarcoma: In Vitro Support for a Novel Drug Repurposing Strategy.

Authors:  Jonathan B Mandell; Feiqi Lu; Matthew Fisch; Jan H Beumer; Jianxia Guo; Rebecca J Watters; Kurt R Weiss
Journal:  Sarcoma       Date:  2019-07-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.